On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would, if a partnership or financing solution was not secured by March 12, 2025, propose to the annual general meeting that the Company shall enter into voluntary liquidation.
Yesterday, March 12, 2025, the Company disclosed a notice convening the annual general meeting, where it is proposed that the Company shall enter voluntary solvent liquidation. If the proposal is adopted, the Company intends to initiate a process for delisting its financial instruments from Nasdaq First North Growth Market.
The rules of First North Growth Market state that a listed company can be given observation status if the issuer has disclosed its intention to enter into liquidation or delist its financial instruments from Nasdaq First North Growth Market.
With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares (SCOL, ISIN code DK0061031895, order book ID 212648) and equity rights (SCOL TO 3, ISIN code DK0062957114, order book ID 345978) in Scandion Oncology A/S.
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
